Unaudited Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	9 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Operating activities:
Net (loss) income	$ (6,226)	$ 5,875
Adjustments to reconcile net (loss) income to net cash provided by operating activities:
Amortization of acquisition-related intangible assets	15,284	15,809
Stock-based compensation plan expense	31,298	31,906
Depreciation and other amortization	19,807	16,767
Gain on sale of cost-method investment	0	(237)
Deferred income tax benefit	(271)	(8,284)
Provision for allowances on accounts receivable	204	167
Amortization of debt issuance costs	310	311
Amortization of discount on investments	(52)	(108)
Loss on disposal of equipment	104	596
Loss on foreign exchange	504	410
Changes in operating assets and liabilities:
Accounts receivable	(2,062)	(3,520)
Prepaid expenses and other current assets	(479)	(3,913)
Operating lease right-of-use asset, net	2,282
Other assets	(1,860)	(1,483)
Accounts payable	2,627	1,485
Accrued expenses	(461)	(1,513)
Operating lease liabilities	(2,125)
Customer account liabilities	1,074	1,562
Deferred revenue	9,577	7,835
Other liabilities	594	(650)
Net cash provided by operating activities	70,129	63,015
Investing activities:
Acquisition of businesses and assets, net of cash and restricted cash acquired	0	(21,449)
Purchases of other investments	(144)	0
Proceeds from sale of cost-method investment	0	237
Purchases of available-for-sale securities	(11,473)	(7,588)
Proceeds from sales of available-for-sale securities	9,900	9,200
Capital expenditures, including capitalization of software costs	(39,516)	(45,725)
Insurance proceeds received for damage to equipment	0	201
Net cash used in investing activities	(41,233)	(65,124)
Financing activities:
Repurchase of common stock	(19,145)	0
Repayment of amounts borrowed under revolving credit facility	(10,000)	(40,000)
Amounts borrowed under revolving credit facility	80,000	0
Repayment of notes payable	(365)	(552)
Settlement of warrants	0	(4)
Debt issuance costs related to credit facility	0	(597)
Proceeds from exercise of stock options and employee stock purchase plan	4,133	3,856
Net cash provided by (used in) financing activities	54,623	(37,297)
Effect of exchange rate changes on cash	(1,667)	(1,427)
Increase (decrease) in cash, cash equivalents and restricted cash	81,852	(40,833)
Cash, cash equivalents and restricted cash at beginning of period	97,801	124,613
Cash, cash equivalents and restricted cash at end of period	179,653	83,780
Cash, cash equivalents and restricted cash at end of period	179,653	83,780
Supplemental disclosures of non-cash financing activities:
Issuance of common stock upon settlement of the warrants	$ 0	$ 58,451